Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00269126 | Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) | PHASE3 | COMPLETED | 150 | — | — | Feb 1, 2005 | Aug 1, 2005 | Apr 15, 2013 | 2 | Japan, |
| Name | Type | Description |
|---|---|---|
| fluticasone propionate/salmeterol combination DISKUS | DRUG | - |
| salmeterol xinafoate | DRUG | - |
Inclusion criteria: * Diagnosis of COPD. Exclusion criteria: * Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder other than COPD. * Other inclusion and exclusion criteria will be evaluated at the first study visit.